Response and Survival with Dacarbazine and Vemurafenib for the Treatment of BRAFV600E-Mutated Melanoma and Dacarbazine and Ipilimumab for the First-Line Treatment of Advanced-Stage Melanoma


Response and Survival with Dacarbazine and Vemurafenib for the Treatment of BRAFV600E-Mutated Melanoma and Dacarbazine and Ipilimumab for the First-Line Treatment of Advanced-Stage Melanoma
Slides from presentations at ASCO 2011 and comments from Keith T Flaherty, MD and Jeffrey Weber, MD, PhD

Chapman PB et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507-16. Abstract

Chapman PB et al. Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma. Proc ASCO 2011;Abstract LBA4.

Dr Flaherty is Associate Professor at Harvard Medical School and Director of Developmental Therapeutics at Massachusetts General Hospital Cancer Center in Boston, Massachusetts.